164 related articles for article (PubMed ID: 38140540)
1. Antiviral Potential of Azelastine against Major Respiratory Viruses.
Fischhuber K; Bánki Z; Kimpel J; Kragl N; Rössler A; Bolze A; Muellauer B; Angerer J; Nagy G; Nagy E; Szijarto V
Viruses; 2023 Nov; 15(12):. PubMed ID: 38140540
[TBL] [Abstract][Full Text] [Related]
2. The Anti-Histamine Azelastine, Identified by Computational Drug Repurposing, Inhibits Infection by Major Variants of SARS-CoV-2 in Cell Cultures and Reconstituted Human Nasal Tissue.
Konrat R; Papp H; Kimpel J; Rössler A; Szijártó V; Nagy G; Madai M; Zeghbib S; Kuczmog A; Lanszki Z; Gesell T; Helyes Z; Kemenesi G; Jakab F; Nagy E
Front Pharmacol; 2022; 13():861295. PubMed ID: 35846988
[No Abstract] [Full Text] [Related]
3. Thapsigargin Is a Broad-Spectrum Inhibitor of Major Human Respiratory Viruses: Coronavirus, Respiratory Syncytial Virus and Influenza A Virus.
Al-Beltagi S; Preda CA; Goulding LV; James J; Pu J; Skinner P; Jiang Z; Wang BL; Yang J; Banyard AC; Mellits KH; Gershkovich P; Hayes CJ; Nguyen-Van-Tam J; Brown IH; Liu J; Chang KC
Viruses; 2021 Feb; 13(2):. PubMed ID: 33546185
[TBL] [Abstract][Full Text] [Related]
4. Repurposing Probenecid to Inhibit SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus (RSV) Replication.
Tripp RA; Martin DE
Viruses; 2022 Mar; 14(3):. PubMed ID: 35337018
[TBL] [Abstract][Full Text] [Related]
5. Influenza A(H1N1)pdm09 Virus but Not Respiratory Syncytial Virus Interferes with SARS-CoV-2 Replication during Sequential Infections in Human Nasal Epithelial Cells.
Fage C; Hénaut M; Carbonneau J; Piret J; Boivin G
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215988
[TBL] [Abstract][Full Text] [Related]
6. In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2.
Signer J; Jonsdottir HR; Albrich WC; Strasser M; Züst R; Ryter S; Ackermann-Gäumann R; Lenz N; Siegrist D; Suter A; Schoop R; Engler OB
Virol J; 2020 Sep; 17(1):136. PubMed ID: 32907596
[TBL] [Abstract][Full Text] [Related]
7. Antiviral Activity of Umifenovir In Vitro against a Broad Spectrum of Coronaviruses, Including the Novel SARS-CoV-2 Virus.
Leneva I; Kartashova N; Poromov A; Gracheva A; Korchevaya E; Glubokova E; Borisova O; Shtro A; Loginova S; Shchukina V; Khamitov R; Faizuloev E
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452529
[TBL] [Abstract][Full Text] [Related]
8. Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2.
Ge S; Lu J; Hou Y; Lv Y; Wang C; He H
Virology; 2021 Aug; 560():110-115. PubMed ID: 34052578
[TBL] [Abstract][Full Text] [Related]
9. A novel film spray containing curcumin inhibits SARS-CoV-2 and influenza virus infection and enhances mucosal immunity.
Nittayananta W; Lerdsamran H; Chutiwitoonchai N; Promsong A; Srichana T; Netsomboon K; Prasertsopon J; Kerdto J
Virol J; 2024 Jan; 21(1):26. PubMed ID: 38263162
[TBL] [Abstract][Full Text] [Related]
10. Hylin-a1: A Pan-Inhibitor against Emerging and Re-Emerging Respiratory Viruses.
Chianese A; Zannella C; Monti A; Doti N; Sanna G; Manzin A; De Filippis A; Galdiero M
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762191
[TBL] [Abstract][Full Text] [Related]
11. 4'-Fluorouridine mitigates lethal infection with pandemic human and highly pathogenic avian influenza viruses.
Lieber CM; Aggarwal M; Yoon JJ; Cox RM; Kang HJ; Sourimant J; Toots M; Johnson SK; Jones CA; Sticher ZM; Kolykhalov AA; Saindane MT; Tompkins SM; Planz O; Painter GR; Natchus MG; Sakamoto K; Plemper RK
PLoS Pathog; 2023 Apr; 19(4):e1011342. PubMed ID: 37068076
[TBL] [Abstract][Full Text] [Related]
12. 4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication.
Sourimant J; Lieber CM; Aggarwal M; Cox RM; Wolf JD; Yoon JJ; Toots M; Ye C; Sticher Z; Kolykhalov AA; Martinez-Sobrido L; Bluemling GR; Natchus MG; Painter GR; Plemper RK
Science; 2022 Jan; 375(6577):161-167. PubMed ID: 34855509
[TBL] [Abstract][Full Text] [Related]
13. Drug-Free Nasal Spray as a Barrier against SARS-CoV-2 and Its Delta Variant: In Vitro Study of Safety and Efficacy in Human Nasal Airway Epithelia.
Fais F; Juskeviciene R; Francardo V; Mateos S; Guyard M; Viollet C; Constant S; Borelli M; Hohenfeld IP
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409423
[TBL] [Abstract][Full Text] [Related]
14. Identification and Characterization of Novel Compounds with Broad-Spectrum Antiviral Activity against Influenza A and B Viruses.
Park JG; Ávila-Pérez G; Nogales A; Blanco-Lobo P; de la Torre JC; Martínez-Sobrido L
J Virol; 2020 Mar; 94(7):. PubMed ID: 31941776
[TBL] [Abstract][Full Text] [Related]
15. Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients.
Klussmann JP; Grosheva M; Meiser P; Lehmann C; Nagy E; Szijártó V; Nagy G; Konrat R; Flegel M; Holzer F; Groß D; Steinmetz C; Scherer B; Gruell H; Schlotz M; Klein F; de Aragão PA; Morr H; Al Saleh H; Bilstein A; Russo B; Müller-Scholtz S; Acikel C; Sahin H; Werkhäuser N; Allekotte S; Mösges R
Sci Rep; 2023 Apr; 13(1):6839. PubMed ID: 37100830
[TBL] [Abstract][Full Text] [Related]
16. Natural Derived Nasal Spray; A Proposed Approach for COVID-19 Disease Control.
Hoseini-Tavassol Z; Ejtahed HS; Soroush AR; Sajjadpour Z; Hasani-Ranjbar S; Larijani B
Infect Disord Drug Targets; 2021; 21(8):e160921191568. PubMed ID: 33602078
[TBL] [Abstract][Full Text] [Related]
17. Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice.
Paull JRA; Luscombe CA; Castellarnau A; Heery GP; Bobardt MD; Gallay PA
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452519
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of influenza A virus and SARS-CoV-2 infection or co-infection by griffithsin and griffithsin-based bivalent entry inhibitor.
Cao N; Cai Y; Huang X; Jiang H; Huang Z; Xing L; Lu L; Jiang S; Xu W
mBio; 2024 May; 15(5):e0074124. PubMed ID: 38587427
[TBL] [Abstract][Full Text] [Related]
19. Respiratory Syncytial Virus Protects Bystander Cells against Influenza A Virus Infection by Triggering Secretion of Type I and Type III Interferons.
Czerkies M; Kochańczyk M; Korwek Z; Prus W; Lipniacki T
J Virol; 2022 Nov; 96(22):e0134122. PubMed ID: 36326278
[TBL] [Abstract][Full Text] [Related]
20. Potent 3CLpro inhibitors effective against SARS-CoV-2 and MERS-CoV in animal models by therapeutic treatment.
Li P; Kim Y; Dampalla CS; Nhat Nguyen H; Meyerholz DK; Johnson DK; Lovell S; Groutas WC; Perlman S; Chang K-O
mBio; 2024 Feb; 15(2):e0287823. PubMed ID: 38126789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
